PITPNM3 and pancreatic ductal adenocarcinoma: PITPNM3 has been demonstrated as a druggable target because it had been discovered to promote breast cancer,[3] hepatocellular carcinoma[5a] and pancreatic ductal carcinoma[6a] metastasis and our systematic analysis revealed its oncogenic roles in pan‐cancer.